{"title":"Exosomes from Cancer-associated Fibroblasts Orchestrate Lung Metastasis of Breast Cancer via LncRNA LMAEP.","authors":"Liyan Lao, Huiping Chen, Huiyi Zeng, Penghan Huang, Yufei Chen, Jianing Chen, Wei Wu, Wenfeng Zeng","doi":"10.7150/jca.139124","DOIUrl":null,"url":null,"abstract":"<p><p>Lung metastasis is a leading cause of patient mortality in breast cancer. Cancer-associated fibroblasts (CAFs), the most abundant stromal cells within the tumor microenvironment, are closely implicated in pulmonary metastasis. Nevertheless, the mechanism underlying CAF-mediated metastasis remains elusive. We found that density of CAFs in primary tumors showed no significant difference in patients with or without lung metastasis. However, CAFs of breast cancer patients with lung metastasis (termed lung metastasis-associated fibroblasts, LMAFs) exhibited immense competence in inducing epithelial-mesenchymal transition (EMT), invasion and proliferation of tumor cells relative to non-metastatic CAFs. LMAF-derived exosomes were sufficient to confer the pro-metastatic phenotype to tumor cells. LncRNA microarray screening identified LMAEP (Lung Metastasis-Associated EMT Promoter) as a lncRNA specifically enriched in LMAF-derived exosomes. Knockdown of LMAEP abrogated the capacity of LMAFs to induce cancer cell EMT, invasion and proliferation. Targeting of lncRNA LMAEP tremendously suppressed tumor growth and lung metastasis of breast cancer <i>in vivo</i>. These findings identify LMAEP as a critical metastasis-inducing mediator of CAFs, positioning it as a potential biomarker for risk prediction and early detection of lung metastasis. Furthermore, targeting exosomal lncRNA LMAEP represents a promising therapeutic strategy for restraining pulmonary metastasis of breast cancer.</p>","PeriodicalId":15183,"journal":{"name":"Journal of Cancer","volume":"17 10","pages":"1783-1796"},"PeriodicalIF":3.4000,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13617416/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/jca.139124","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Lung metastasis is a leading cause of patient mortality in breast cancer. Cancer-associated fibroblasts (CAFs), the most abundant stromal cells within the tumor microenvironment, are closely implicated in pulmonary metastasis. Nevertheless, the mechanism underlying CAF-mediated metastasis remains elusive. We found that density of CAFs in primary tumors showed no significant difference in patients with or without lung metastasis. However, CAFs of breast cancer patients with lung metastasis (termed lung metastasis-associated fibroblasts, LMAFs) exhibited immense competence in inducing epithelial-mesenchymal transition (EMT), invasion and proliferation of tumor cells relative to non-metastatic CAFs. LMAF-derived exosomes were sufficient to confer the pro-metastatic phenotype to tumor cells. LncRNA microarray screening identified LMAEP (Lung Metastasis-Associated EMT Promoter) as a lncRNA specifically enriched in LMAF-derived exosomes. Knockdown of LMAEP abrogated the capacity of LMAFs to induce cancer cell EMT, invasion and proliferation. Targeting of lncRNA LMAEP tremendously suppressed tumor growth and lung metastasis of breast cancer in vivo. These findings identify LMAEP as a critical metastasis-inducing mediator of CAFs, positioning it as a potential biomarker for risk prediction and early detection of lung metastasis. Furthermore, targeting exosomal lncRNA LMAEP represents a promising therapeutic strategy for restraining pulmonary metastasis of breast cancer.
期刊介绍:
Journal of Cancer is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer. The Journal is supported by an international editorial board consisting of a distinguished team of cancer researchers. Journal of Cancer aims at rapid publication of high quality results in cancer research while maintaining rigorous peer-review process.